SEC Form 4 · accession 0001587221-18-000031
Zosano Pharma Corp · ZSAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kleanthis G Xanthopoulos
Director
Period of report
May 31, 2018
Accepted (ET)
Jun 1, 2018 · 7:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001587221
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $4.24 | May 31, 2018 | A | 25,000 | A | — | Apr 16, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option grant was approved by the compensation committee of the Company's board of directors on April 16, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on May 31, 2018.
- F2The shares underlying the stock option vest in equal monthly installments over a four-year period, beginning on May 16, 2018, so that all shares shall have vested on April 16, 2022.